Hemo

Hemoglobin Testing at the Point of Care

Since the level of blood oxygenation can be an essential element of patient assessment, measurement of hemoglobin levels in the clinical setting is often desirable. In keeping with the recent trend to incorporate sophisticated technology into easily used point-of-care devices, recent products from several manufacturers offer prompt assessment of hemoglobin values. HemoCue, Inc., Lake...

Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent

Results Highlighted in Oral Presentation at International Symposiumof Thrombosis and Haemostasis GENEVA, July 10, 2007 /PRNewswire-FirstCall/ -- BaxterHealthcare Corporation today announced the presentation of findingsfrom the ADAPT (Analysis of Data from ADVATE(R) Prospective Trials)study program database showing a statistically significantrelationship between the duration of time spent...

Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting

GENEVA, July 11, 2007 /PRNewswire/ -- InspirationBiopharmaceuticals today announced the presentation of preclinicaldata supporting the development of new, proprietary forms ofrecombinant Factor IX to treat patients with Hemophilia B. The datawere highlighted in an oral presentation and a poster session atthe XXIst Congress of the International Society on Thrombosis andHaemostasis (ISTH)...

In Vitro and In Vivo Data Show Alfacell's Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells

Pre-Clinical Results Demonstrate Potential of ONCONASE forTreatment of Neuroblastoma BLOOMFIELD, N.J., June 27, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation today announced that new data show ONCONASE,the company's lead drug candidate, is active against naive andchemoresistant neuroblastoma cells. The pre-clinical in vitro and in vivo data published in CancerLetters (2007; Vo...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007/PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announcedpreliminary results from two open-label, multi-center Phase 2clinical trials supporting the potential use of Xcytrin(R)(motexafin gadolinium) Injection, the company's lead productcandidate, in combination with Alimta(R) (pemetrexed) and incombination with Taxotere(R) (docetaxel...

July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of Factive Tablets for Five-Day Treatment of Community-Acquired Pneumonia

WALTHAM, Mass.--(BUSINESS WIRE)--Jun 12, 2007 - Results from thesuccessful clinical trial of Oscient Pharmaceuticals' (Nasdaq:OSCI) FACTIVE(R) (gemifloxacin mesylate) tablets for the five-daytreatment of community-acquired pneumonia of mild to moderateseverity (CAP) have been published in the July issue of thepeer-reviewed Journal of Antimicrobial Chemotherapy, currentlyavailable in advance...

New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy

CHICAGO--(BUSINESS WIRE)--Jun 4, 2007 - Pfizer announced today thataxitinib (AG-013736), an investigational oral, selective inhibitorof VEGFR 1, 2,3 (vascular endothelial growth factor receptors 1, 2,3) combined with gemcitabine showed a trend towards prolongedoverall survival (OS) in patients with advanced pancreatic cancer,compared with gemcitabine alone, according to preliminary data from...

Eloxatin (oxaliplatin injection)-Based Chemotherapy Sets New Treatment Benchmark in Patients With Metastatic Colorectal Cancer

FOLFOX4 Chemotherapy Results in Improved Long-term [Five-years]Overall Survival for these Seriously Ill Patients CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- FOLFOX4, anEloxatin(R)-based chemotherapy regimen, provided significantimprovements in long-term [five- years] overall survival (OS) andtime to disease progression (TTP) - a longer period of stabledisease - in patients with metas...

Hyperthermia Plus Chemotherapy Nearly Doubles Disease-Free Survival Compared to Chemotherapy Alone for Sarcoma Cancer Patients

SALT LAKE CITY, June 04, 2007 /PRNewswire-FirstCall/ -- BSDMedical Corp. announced today that the results of a 340 patientrandomized Phase III clinical trial testing the benefit of addinghyperthermia therapy to chemotherapy were presented at the annualAmerican Society of Clinical Oncology (ASCO) conference underway inChicago, Illinois. According to the results of this clinical study,whic...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with epratuzumab plus standardchemotherapy is feasible...

MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone

Seven year follow up of pivotal trial confirms that more patientsare alive today due to MabThera BASEL, Switzerland, June 4, 2007-A follow-up analysis trackingthe outcome of patients with aggressive non-Hodgkin's lymphoma(NHL) who were treated with the innovative cancer therapy MabThera(rituximab) over seven years ago has revealed exciting results(1). This analysis of the original...

ChemoCentryx Presents Positive Phase 2 Clinical Data for Traficet-EN in Crohn's Disease at the Digestive Disease Week 2007 Conference

Clear Anti-Inflammatory Activity Demonstrated Among Patients withActive Disease MOUNTAIN VIEW, Calif., May 23, 2007 /PRNewswire/ --ChemoCentryx, Inc., a clinical-stage biopharmaceutical companyfocused on discovering, developing and commercializingorally-administered therapeutics that target the chemokine system,presented data today from the company's Phase 2 clinical trial ofTraficet-EN...

Prostate Cancer: Clinical Study Demonstrates Superior Efficacy of Docetaxel Chemotherapy

VIENNA, Austria, May 23, 2007-The chemotherapy drugdocetaxel currently offers the best treatment forandrogen-independent prostate cancer. That is the result of a nowpublished clinical trial that compared the efficacy of the two mostwidely used chemotherapy drugs. When using docetaxel, the risk ofdisease progression was cut by more than 50% than when using thenext-best chemotherapy drug.<...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

Data published today in the Journal of the National CancerInstitute BASEL, Switzerland, 2 May 2007 - In a study published today inthe Journal of the National Cancer Institute, the innovative cancerdrug MabThera was shown to improve overall survival in patientswith lymphoma regardless of the chemotherapy regimen used.1 Thereview further s...

Abraxis BioScience Presents Data from Pre-Clinical Study That Provide Evidence for Chemotherapy-Induced Angiogenesis and Rationale for Combining nab-Paclitaxel (Abraxane) with Anti-Angiogenic Agents to Increase Tumor Response

LOS ANGELES--(BUSINESS WIRE)--Apr 19, 2007 - Abraxis BioScience,Inc. (NASDAQ:ABBI), an integrated, global biopharmaceuticalcompany, discussed results from two pre-clinical studies thatprovide evidence for chemotherapy induced angiogenesis andrationale for combining nab-paclitaxel (ABRAXANE(R) for InjectableSuspension (paclitaxel protein-bound particles for injectablesuspension) (albumin-bou...

Viventia biotech reports synergystic effect of its Proxinium antibody in combinaton with chemotherapy and radiation

- Results Reported at the American Association for Cancer Research(AACR) Annual Meeting - TORONTO, April 18, 2007 /PRNewswire/ - Viventia Biotech Inc., aprivately held biopharmaceutical company advancing a portfolio ofnovel antibody products focused on cancer, today announced resultsof in vitro cytotoxicity and in vivo pharmacokinetic studiesconducted to evaluate the potential for combini...

Onconase has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting

BLOOMFIELD, N.J., April 18, 2007 /PRNewswire-FirstCall/ --ONCONASE (ranpirnase), Alfacell Corporation's lead drug candidate,may have potential as a chemopreventive agent, according toworld-renowned mesothelioma researcher Michele Carbone M.D., Ph.D.,at this week's American Association for Cancer Research (AACR)Annual Meeting. In a series of poster presentations, Dr. Carbone highlig...

Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual Meeting

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Apr 16, 2007 - Amgen(Nasdaq:AMGN) today presented the results from a randomized,double-blind, placebo-controlled Phase 3 study evaluating theefficacy and safety of Aranesp(R) (darbepoetin alfa) for thetreatment of anemia in patients with active cancer not receivingchemotherapy or radiotherapy ("the 103 study"). Aranesp is notapproved for use by the FD...

Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase Ib/II Clinical Trial in Late Stage Cancer Patients

TSX: CTI OTCBB: CHKT VANCOUVER, March 12, 2007 /PRNewswire-FirstCall/ - ChemokineTherapeutics Corp. ("Chemokine Therapeutics" or the "Company") , abiotechnology company developing chemokine-based therapies to treatcancer, blood disorders, and vascular disease today announcedpositive preliminary data and the successful completion of thedose-escalation portion of its Phase Ib/II clinical tr...